文献速递病毒性肝炎

格鲁吉亚丙型肝炎消除项目三年进展(2015年4月-2018年3月)

Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
PubMed 文献 · Clin Infect Dis · 2020-01-01

格鲁吉亚于2015年4月启动全球首个丙肝消除项目,本研究基于估计15万成人活跃HCV感染构建照护级联。

要点

  • 估计15万慢性HCV成人中,35.1%被诊断,30.2%启动治疗,19.4%获SVR。
  • 符合方案分析SVR率98.2%,意向治疗分析78.1%。

核心结论

  • 格鲁吉亚在丙肝消除道路上取得实质性进展。
  • 需扩大检测和诊断,并有效链接治疗服务以实现消除目标。

研究设计与样本

  • 基于估计15万≥18岁活跃HCV感染成人构建HCV照护级联。
  • 纳入2015年4月至2018年3月筛查或进入治疗项目的所有患者。
  • 筛查数据来自国家HCV筛查数据库,治疗数据来自国家HCV治疗项目数据库。

关键数值与推荐

  • 可用治疗方案包括索非布韦和雷迪帕韦/索非布韦为基础方案。

临床怎么用

  • 需扩大HCV检测和诊断覆盖。
  • 应加强有效链接至治疗服务以提高消除目标达成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In April 2015, in collaboration with the US Centers for Disease Control and Prevention and Gilead Sciences, the country of Georgia embarked on the world's first hepatitis C elimination program. We aimed to assess progress toward elimination targets 3 years after the start of the elimination program. METHODS: We constructed a hepatitis C virus (HCV) care cascade for adults in Georgia, based on the estimated 150 000 persons aged ≥18 years with active HCV infection. All patients who were screened or entered the treatment program during April 2015-March 2018 were included in the analysis. Data on the number of persons screened for HCV were extracted from the national HCV screening database. For the treatment component, we utilized data from the Georgia National HCV treatment program database. Available treatment options included sofosbuvir and ledipasvir/sofosbuvir-based regimens. RESULTS: Since April 2015, a cumulative 974 817 adults were screened for HCV antibodies; 86 624 persons tested positive, of whom 61 925 underwent HCV confirmatory testing. Among the estimated 150 000 adults living with chronic hepatitis C in Georgia, 52 856 (35.1%) were diagnosed, 45 334 (30.2%) initiated treatment with direct-acting antivirals, and 29 090 (19.4%) achieved a sustained virologic response (SVR). Overall, 37 256 persons were eligible for SVR assessment; of these, only 29 620 (79.5%) returned for evaluation. The SVR rate was 98.2% (29 090/29 620) in the per-protocol analysis and 78.1% (29 090/37 256) in the intent-to-treat analysis. CONCLUSIONS: Georgia has made substantial progress in the path toward eliminating hepatitis C. Scaling up of testing and diagnosis, along with effective linkage to treatment services, is needed to achieve the goal of elimination.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Tsertsvadze T, Gamkrelidze A, Chkhartishvili N, et al. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018. Clin Infect Dis. 2020. PMID: 31563938. doi:10.1093/cid/ciz956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。